Clinical Fellowships
Supports U.S. academic cardiology fellowships to train physicians in diagnosing, treating, and researching Transthyretin-mediated (ATTR) Amyloidosis through clinical education and scientific advancement.
Funder: Alnylam Pharmaceuticals
Due Dates: August 15, 2025 | August 28, 2026
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds support fellow salary and benefits only.
Summary: Supports U.S. academic Cardiology Fellowship Programs to train physicians in the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis.
Key Information: Only ACGME-accredited institutions with active Cardiology Fellowship Programs are eligible; funding does not cover indirect costs or overhead.
Description
This program provides institutional grants to support educational clinical fellowships within U.S. academic organizations, specifically aiming to advance physician training in the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis. The goal is to foster multidisciplinary collaboration, improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into patient-centered care. Funding is awarded to institutions, not individuals, and is intended to support the salary and benefits of clinical fellows.
